{
  "trial_id": "NCT00967369",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, race, ECOG performance status, prior chemotherapy regimens, baseline disease characteristics (e.g., size and location of lesions), absolute neutrophil count (ANC), platelet count, hemoglobin level, serum bilirubin level, alkaline phosphatase level, aspartate aminotransferase (AST) level, alanine aminotransferase (ALT) level, serum creatinine level, pregnancy status (for females of childbearing potential), contraceptive use (for males and females of childbearing potential), history of other primary malignancies, history of cardiovascular conditions, history of infections (HIV, hepatitis B or C), presence of peripheral neuropathy, hypersensitivity to boron or mannitol, prior bortezomib therapy, use of corticosteroids, presence of systemic infections.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "A Randomized Phase II Study of Bortezomib Plus ICE (BICE) Versus Standard ICE for Patients with Rela",
          "ECOG performance status"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "prior chemotherapy regimens",
        "baseline disease characteristics (e.g., size and location of lesions)",
        "absolute neutrophil count (ANC)",
        "platelet count",
        "hemoglobin level",
        "serum bilirubin level",
        "alkaline phosphatase level",
        "aspartate aminotransferase (AST) level",
        "alanine aminotransferase (ALT) level",
        "serum creatinine level",
        "pregnancy status (for females of childbearing potential)",
        "contraceptive use (for males and females of childbearing potential)",
        "history of other primary malignancies",
        "history of cardiovascular conditions",
        "history of infections (HIV, hepatitis B or C)",
        "presence of peripheral neuropathy",
        "hypersensitivity to boron or mannitol",
        "prior bortezomib therapy",
        "use of corticosteroids",
        "presence of systemic infections"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG performance status, Absolute neutrophil count, Platelet count, Hemoglobin, Serum bilirubin, Alkaline phosphatase, Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Serum creatinine, Prior chemotherapy regimen, Prior stem cell transplant, Presence of CNS involvement, HIV status, Hepatitis B or C status, Peripheral neuropathy grade, Contraceptive use, ",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)",
        "A Randomized Phase II Study of Bortezomib Plus ICE (BICE) Versus Standard ICE for Patients with Rela"
      ],
      "remaining_candidate_features": [
        "ECOG performance status",
        "Absolute neutrophil count",
        "Platelet count",
        "Hemoglobin",
        "Serum bilirubin",
        "Alkaline phosphatase",
        "Aspartate aminotransferase (AST)",
        "Alanine aminotransferase (ALT)",
        "Serum creatinine",
        "Prior chemotherapy regimen",
        "Prior stem cell transplant",
        "Presence of CNS involvement",
        "HIV status",
        "Hepatitis B or C status",
        "Peripheral neuropathy grade",
        "Contraceptive use"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Absolute Neutrophil Count, Platelet Count, Hemoglobin, Serum Bilirubin, Alkaline Phosphatase, Aspartate Aminotransferase, Alanine Aminotransferase, Serum Creatinine, Number of Prior Chemotherapy Regimens, Time Since Last Chemotherapy, Presence of B Symptoms, International Prognostic Score.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "A Randomized Phase II Study of Bortezomib Plus ICE (BICE) Versus Standard ICE for Patients with Rela"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "ECOG Performance Status",
        "Absolute Neutrophil Count",
        "Platelet Count",
        "Hemoglobin",
        "Serum Bilirubin",
        "Alkaline Phosphatase",
        "Aspartate Aminotransferase",
        "Alanine Aminotransferase",
        "Serum Creatinine",
        "Number of Prior Chemotherapy Regimens",
        "Time Since Last Chemotherapy",
        "Presence of B Symptoms",
        "International Prognostic Score"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ECOG performance status, number of prior chemotherapy regimens, time since diagnosis, time since last treatment, presence of B symptoms, bulky disease, International Prognostic Score (IPS) at diagnosis, IPS at relapse, serum lactate dehydrogenase (LDH) level, serum beta-2 microglobulin level.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "A Randomized Phase II Study of Bortezomib Plus ICE (BICE) Versus Standard ICE for Patients with Rela",
          "ECOG performance status"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "number of prior chemotherapy regimens",
        "time since diagnosis",
        "time since last treatment",
        "presence of B symptoms",
        "bulky disease",
        "International Prognostic Score (IPS) at diagnosis",
        "IPS at relapse",
        "serum lactate dehydrogenase (LDH) level",
        "serum beta-2 microglobulin level"
      ]
    }
  }
}